Gossamer Bio, Inc. reported its financial results for the third quarter and the nine months ended September 30, 2024, highlighting significant changes in revenue and operating performance compared to the previous fiscal period. The company generated total revenue of $9.5 million for the third quarter and $105.3 million for the nine months, a substantial increase from $0 in the same periods of 2023. This revenue primarily stemmed from the Chiesi Collaboration Agreement, which included a one-time development cost reimbursement and ongoing cost-sharing payments for research and development services.
Operating expenses for the third quarter totaled $43.4 million, up from $40.5 million in the prior year, while expenses for the nine months decreased to $129.1 million from $134.7 million. The net loss for the third quarter was $30.8 million, a notable improvement from a loss of $40.0 million in the same quarter of 2023. For the nine months, the net loss was $23.5 million, significantly reduced from $131.7 million in the previous year.
Research and development expenses for the third quarter increased to $34.9 million, compared to $31.2 million in 2023, while for the nine months, these expenses decreased to $102.4 million from $105.3 million. The company reported that expenses related to the seralutinib program rose to $32.8 million for the third quarter, up from $27.0 million in the prior year.
As of September 30, 2024, Gossamer Bio had cash and cash equivalents of $28.5 million, down from $32.1 million at the end of 2023, while marketable securities increased to $298.6 million from $264.3 million. The total assets rose to $350.9 million, compared to $311.9 million at the end of 2023. The accumulated deficit stood at $1.24 billion, reflecting ongoing operational losses.
Strategically, the company entered into a significant collaboration agreement with Chiesi Farmaceutici S.p.A. in May 2024, which includes a $160 million upfront payment and potential milestone payments totaling up to $374 million. This partnership is aimed at the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gossamer Bio also terminated its Credit Facility in May 2024, discharging an outstanding debt balance of $7.7 million, and as of September 30, 2024, the company had no debt outstanding. The company anticipates needing to raise additional capital to support ongoing research and development efforts, with future financing potentially diluting existing stockholders' ownership interests.
About Gossamer Bio, Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.